Open Access

Complete response of MSI‑high metastatic colon cancer following treatment with regorafenib: A case report

  • Authors:
    • Hyungjoo Baik
    • Hee Ju Lee
    • Jueun Park
    • Ha Young Park
    • Jinyoung Park
    • Sunseong Lee
    • Ki Beom Bae
  • View Affiliations

  • Published online on: September 24, 2021     https://doi.org/10.3892/mco.2021.2405
  • Article Number: 243
  • Copyright: © Baik et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Regorafenib has been demonstrated to prolong survival in patients with metastatic colorectal cancer refractory to standard chemotherapy. However, overall survival is limited to 2.5 months. The present report describes a unique case of metastatic colon cancer, which showed a complete response to regorafenib. A 54‑year‑old woman was diagnosed with right colon cancer obstruction with peritoneal seeding. The patient underwent laparoscopic right hemicolectomy, and the pathology was T4aN2bM1, moderately differentiated adenocarcinoma with high microsatellite instability (MSI‑H) and wild‑type KRAS/NRAS. The first‑line chemotherapy was fluorouracil, leucovorin and irinotecan with cetuximab. After 12 cycles, recurrence at the anastomotic site was identified. The patient underwent palliative colectomy, and superior mesenteric artery (SMA) lymph node metastases were evident. The patient received second‑line chemotherapy of fluorouracil, leucovorin and oxaliplatin with bevacizumab. Progression of metastasis to the right common iliac lymph nodes was detected after only four cycles of therapy. Thereafter, the patient received regorafenib as third‑line therapy, starting with 160 mg for two cycles and reducing the dose thereafter, for a total of 17 cycles. The previously confirmed SMA lymph node metastasis had disappeared after the seventh cycle, and the right common iliac lymph node metastasis was not visible on CT after the 16th cycle. The patient decided to terminate regorafenib and has not experienced recurrence 2 years since treatment cessation. This is the first report of refractory metastatic colon cancer with MSI‑H showing a complete response to regorafenib. Further studies are required to investigate the efficacy of regorafenib in refractory metastatic colon cancer with MSI‑H and to elucidate the mechanism of remission.
View Figures
View References

Related Articles

Journal Cover

November-2021
Volume 15 Issue 5

Print ISSN: 2049-9450
Online ISSN:2049-9469

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Baik H, Lee HJ, Park J, Park HY, Park J, Lee S and Bae KB: Complete response of MSI‑high metastatic colon cancer following treatment with regorafenib: A case report. Mol Clin Oncol 15: 243, 2021
APA
Baik, H., Lee, H.J., Park, J., Park, H.Y., Park, J., Lee, S., & Bae, K.B. (2021). Complete response of MSI‑high metastatic colon cancer following treatment with regorafenib: A case report. Molecular and Clinical Oncology, 15, 243. https://doi.org/10.3892/mco.2021.2405
MLA
Baik, H., Lee, H. J., Park, J., Park, H. Y., Park, J., Lee, S., Bae, K. B."Complete response of MSI‑high metastatic colon cancer following treatment with regorafenib: A case report". Molecular and Clinical Oncology 15.5 (2021): 243.
Chicago
Baik, H., Lee, H. J., Park, J., Park, H. Y., Park, J., Lee, S., Bae, K. B."Complete response of MSI‑high metastatic colon cancer following treatment with regorafenib: A case report". Molecular and Clinical Oncology 15, no. 5 (2021): 243. https://doi.org/10.3892/mco.2021.2405